E. David Crawford, MD, and Daniel P. Petrylak, MD, discuss PARP inhibition, TALAPRO-3, HRR alterations, and genomic testing in metastatic prostate cancer.
Read More
E. David Crawford, MD, and Daniel P. Petrylak, MD, discuss BET and DNMT inhibition in lineage-plastic prostate cancer associated with TP53 or RB1 loss.
Read More
Dr. Susan F. Slovin explores why immunotherapy remains a promising strategy for selected patients with advanced prostate cancer, reviewing CAR T-cell therapy, bispecific T-cell engagers, emerging immune targets, and lessons from an exceptional clinical response.
Read More
Dr. Scott B. Sellinger reviews PTEN deficiency, AKT signaling, and CAPItello-281 findings in metastatic hormone-sensitive prostate cancer.
Read More
Dr. Khera reviews controversies in testosterone therapy, including prostate cancer, cardiovascular risk, and evolving treatment roles.
Read More